Home About ATSDR Press Room A-Z Index Glossary Employment Training Contact Us CDC  
ATSDR/DHHS Agency for Toxic Substances and Disease Registry Agency for Toxic Substances and Disease Registry Department of Health and Human Services ATSDR en Español

Search:

Section Contents
 
Learning Objectives
Introduction
Key Points
Progress Check
 
Case Contents
 
Table of Contents
Cover Page
How to Use the Course
Initial Check
Mass Casualty Events
Cholinesterase Inhibitors
Pathological Conditions
Cholinergic Toxidrome
Nicotinic Receptors
Muscarinic Receptors
Nicotinic/Muscarinic Mixture
Signs and Symptoms
Laboratory Tests
Differential Diagnosis
Pediatric Cases
Exposure History
RBC & Serum Tests
Inhibitors & Byproducts
Management Strategies
Secondary Exposure
Supportive Care
First-Line Medications
Medications: Atropine
Medications: Pralidoxime
Medications: Diazepam
Antidote Stocking
Deprecated Treatments
Intermediate Syndrome
Delayed Neuropathy
Chronic Neurotoxicity
Other Issues
Posttest
Literature Cited
 
Related Documents
 
MMG: Nerve Agents
ToxFAQs™: Nerve Agents
 
Case Studies (CSEM)
 
CSEM Home
Continuing Education
Online Registration
 
ATSDR Resources
 
Case Studies (CSEM)
Exposure Pathways
GATHER (GIS)
Health Assessments
Health Statements
Interaction Profiles
Interactive Learning
Managing Incidents
Medical Guidelines
Minimal Risk Levels
Priority List
ToxFAQs™
ToxFAQs™ CABS
Toxicological Profiles
Toxicology Curriculum
 
External Resources
 
CDC
eLCOSH
EPA
Healthfinder®
Medline Plus
NCEH
NIEHS
NIOSH
OSHA
 

Agency for Toxic Substances and Disease Registry
Case Studies in Environmental Medicine (CSEM) 

Cholinesterase Inhibitors
Including Insecticides and Chemical Warfare Nerve Agents
Part 4: The Cholinergic Toxidrome
Section 12: Public Health and Medico-Legal Issues


Learning Objectives

Upon completion of this section, you should be able to

  • Describe the importance of notifying public health authorities and other emergency response agencies in poisonings due to cholinesterase inhibitors.

Introduction

Healthcare workers are often the first to identify a sentinel patient in what turns out to be a full-blown disease outbreak, (Reigart and Roberts 1999) disaster, or terrorist attack.

Several actions are important to take to reduce morbidity and mortality in cholinesterase poisoning cases.

  • Notification of appropriate public health agencies.
  • Determination if the patient’s history suggests that others may also have been exposed.
  • If information suggests the possibility of a multi-casualty or terrorist event, prompt notification of other emergency response agencies in the area (e.g., area hospitals, clinics, urgent care centers, private physician offices, emergency management offices, fire departments, police, EMS providers, hazmat teams and poison centers) so they can have advance notice and be prepared to handle a hazardous materials emergency.

Saving of clothing, body fluids, and belongings in a safe, secured area in case needed for evidence (preserve the chain of evidence). This should be done in a way that also protects against secondary exposure.


Key Points

  • Accidents and terrorist attacks involving cholinesterase inhibitors have the potential of affecting multiple victims.
  • An important aspect of patient management is to notify public health agencies, and other emergency response agencies (e.g., fire departments, police, EMS providers, hazmat teams, poison centers, and other hospitals, clinics, urgent care centers, and private physician offices) accomplishing this task rapidly.
  • Isolate and save potential forensic evidence (e.g., clothing, body fluid samples, and belongings).

Progress Check

44. Which of the area emergency response agencies should be promptly notified in the event of a cholinesterase inhibitor exposure with the potential for multiple victims? (Choose ALL correct answers)

A. Area EMS providers.
B. Private physicians’ offices.
C. The local/regional poison center.
D. The public health agency.
E. None of the above.

Answer:

To review relevant content, see Introduction in this section.


Previous Section

Next Section

Revised 2007-10-16.